Genmab/GSK's Arzerra gets EU recommendation for chronic lymphocytic leukaemia
25 January 2010
Malini Guha
Genmab/GlaxoSmithKline's anti-CD20 monoclonal antibody drug Arzerra (ofatumumab) has been recommended by the EU's
CHMP for patients with refractory chronic lymphocytic leukaemia (CLL).
Arzerra is intended for the treatment of patients who are refractory to both fludarabine and alemtuzumab (Bayer/Millennium/Genzyme's...
Please Login to read the full article.
25 January 2010
Malini Guha
Arzerra is intended for the treatment of patients who are refractory to both fludarabine and alemtuzumab (Bayer/Millennium/Genzyme's...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US judgement in anti-CD20 Mab suit favours GSK's Arzerra: Genentech/Biogen to appeal
- Micromet teams with US NCI to expand BiTE antibody development
- 7th Annual Scrip Awards: Novartis, Jimenez, Burrill, Glenmark, ICON win
- Mundipharma pays Allos $50 million up front for ex-US rights to lymphoma drug
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
